Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, Sjekloca N, Stwalley B, Stokes M, Taylor A, Nanda R. Kalinsky K, et al. Among authors: bhave ma. Breast Cancer Res Treat. 2024 Nov;208(1):203-214. doi: 10.1007/s10549-024-07412-9. Epub 2024 Jun 21. Breast Cancer Res Treat. 2024. PMID: 38904892 Free PMC article.
A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.
Lawal IO, Adediran OA, Muzahir S, Friend S, Bhave MA, Meisel J, Torres MA, Styblo TM, Graham C, Holbrook A, Kalinsky K, Fielder B, Crowe RJ, Ulaner GA, Schuster DM. Lawal IO, et al. Among authors: bhave ma. Clin Nucl Med. 2023 Jan 1;48(1):e26-e27. doi: 10.1097/RLU.0000000000004385. Epub 2022 Sep 6. Clin Nucl Med. 2023. PMID: 36469077 Free PMC article.
A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment.
Adediran OA, Lawal IO, Muzahir S, Bhave MA, Friend S, Fielder B, Meisel J, Torres MA, Styblo TM, Graham C, Holbrook A, Kalinsky K, Crowe RJ, Ulaner GA, Schuster DM. Adediran OA, et al. Among authors: bhave ma. Clin Nucl Med. 2023 Apr 1;48(4):e202-e203. doi: 10.1097/RLU.0000000000004565. Epub 2023 Jan 14. Clin Nucl Med. 2023. PMID: 36728139
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, Chi JJ, Zeng L, Lee JY, Xue Y, Lu X, Cristofanilli M, Gradishar WJ, Henry CJ, Gillespie TW, Bhave MA, Kalinsky K, Fu H, Bahar I, Zhang B, Wan Y. Zhu Y, et al. Among authors: bhave ma. J Clin Invest. 2024 Mar 26;134(10):e176390. doi: 10.1172/JCI176390. J Clin Invest. 2024. PMID: 38530357 Free PMC article.
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K. Bhave MA, et al. Breast Cancer Res Treat. 2024 Oct;207(3):599-609. doi: 10.1007/s10549-024-07376-w. Epub 2024 Jun 14. Breast Cancer Res Treat. 2024. PMID: 38872062 Free PMC article.
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
Mushtaq A, Lawal IO, Muzahir S, Friend SC, Bhave M, Meisel JL, Torres MA, Styblo TM, Graham CL, Kalinsky K, Switchenko J, Ulaner GA, Schuster DM. Mushtaq A, et al. Among authors: bhave m. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4073-4082. doi: 10.1007/s00259-024-06830-7. Epub 2024 Jul 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38976035 Clinical Trial.
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K. Bhave MA, et al. Breast Cancer Res Treat. 2024 Oct;207(3):611-614. doi: 10.1007/s10549-024-07427-2. Breast Cancer Res Treat. 2024. PMID: 39002070 Free PMC article. No abstract available.
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, Carter S, Bidard FC, Fasching PA, Aftimos P, Wheatley D, Hamilton E, Aft R, Kulkarni S, Schmid P, Bhave M, Ismail-Khan R, Karacsonyi C, Estrem ST, Nguyen B, Ozbek U, Yuen E, Rodrik-Outmezguine V, Ciruelos E. Neven P, et al. Clin Cancer Res. 2024 Dec 2;30(23):5304-5313. doi: 10.1158/1078-0432.CCR-24-2113. Clin Cancer Res. 2024. PMID: 39377773 Free PMC article. Clinical Trial.
19 results